PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY SPECIFICALLY BINDING WITH THE N-TERMINAL OF LYSYL-TRNA SYNTHETASE AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CELL MIGRATION Russian patent published in 2021 - IPC A61K39/395 C07K16/40 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the field of medicine and the pharmaceutical industry. The first object is a pharmaceutical composition containing an effective amount of an antibody or a functional fragment thereof that specifically binds to the N-terminus of lysyl tRNA synthetase (KRS) for the prevention or treatment of a disease associated with the migration of immune cells selected from the group consisting of cardiovascular - vascular disease, fibrotic disease, inflammatory disease, and Alport syndrome, where the antibody contains: (a) a heavy chain variable region cotaining CDR1 containing a SYDMS sequence; CDR2 containing the sequence X₁IX₂X₃X₄X₅GX₆X₇YYADSVKG, and where X₁ is A or V, X₂ is S, D or G, X₃ is Y, P, S or A, X₄ is D, Q, L or Y, X₅ is N, M, S or G, X₆ is N, R or P, X₇ is T, V, I or S; and CDR3 containing the sequence X₈ALDFDY, where X₈ is M or L, and (b) a light chain variable region comprising CDR1 containing the sequence TGSSSNIGSNYVT; CDR2 containing the sequence X₉NX₁₀X₁₁RPS where X₉ is D, S or R, X₁₀ is S or N and X₁₁ is N or Q; and CDR3 containing the sequence X₁₂SFSDELGAYV, where X₁₂ is A or S. The second and third objects are the use of an antibody or a functional fragment thereof to obtain an agent for the prevention or treatment of diseases and a method of treating diseases associated with the migration of immune cells.

EFFECT: technical result consists in the effectiveness of the use of the antibody for the prevention or treatment of diseases caused by the migration of immune cells, due to the binding of the N-end of the KRS.

8 cl, 27 dwg, 12 tbl, 9 ex